"The oral argument in Hikma v. Amarin inadvertently exposed a deeper flaw-not just in inducement doctrine, but in the entire Hatch-Waxman framework. What we are witnessing is the inevitable unraveling of a system built on what Austrian economist F.A. Hayek famously called the 'fatal conceit': the belief that policymakers can engineer complex markets from the top down."
"Hatch-Waxman rests on precisely that conceit. It assumes regulators can finely calibrate incentives-accelerating generic entry while preserving innovation-through devices like 'skinny labels.' But as the argument made clear, real-world behavior refuses to cooperate with this design."
"When the government suggested Hikma's product is essentially 'the same stuff,' it underscored a reality anyone familiar with pharmaceutical markets understands: doctors and patients do not parse labels with legalistic precision. They are far more practical, responding to price, access, and therapeutic substitutability."
The Supreme Court heard arguments in Hikma Pharmaceuticals USA v. Amarin Pharma, Inc., focusing on skinny labeling and induced infringement in patent law. Justices expressed skepticism about new rules for inducement, fearing harm to the generic industry. Commentators noted flaws in the Hatch-Waxman Act's balance, suggesting the Court may reinforce existing legal standards. The case highlights the disconnect between regulatory assumptions and real-world pharmaceutical market behaviors, where practical considerations often override legal definitions.
Read at IPWatchdog.com | Patents & Intellectual Property Law
Unable to calculate read time
Collection
[
|
...
]